



February 3, 2010



To whom it may concern:

Name of Company: NIPRO CORPORATION

Name of Representative: Minoru Sano, President and
Representative Director

(Code No. 8086; First Section of Tokyo Stock Exchange
and Osaka Securities Exchange)

Contact: Kimihito Minoura, Director, General Manager,
CORPORATE PLANNING DIVISION)

(Phone: +81-6-6375-6700)

NIPRO CORPORATION AGREES TO ACQUIRE HOME DIAGNOSTICS, INC.

NIPRO CORPORATION announced that it has signed a definitive agreement with Home Diagnostics, Inc. (headquarters: Florida, United States; "HDI"), a leading manufacturer and marketer of diabetes testing supplies in the United States and listed on the NASDAQ stock exchange, under which agreement NIPRO will offer to acquire HDI through a cash tender offer by a wholly owned subsidiary of NIPRO ("Tender Offer") and a subsequent second-step merger with cash paid as consideration ("Transaction").

On the basis of the aforementioned agreement, NIPRO will offer to acquire all of HDI's outstanding common stock for a total amount of US\$215 million (US\$11.50 per share) through the Tender Offer by Nippon Product Acquisition Corporation ("NPAC"), a newly established acquisition company in the United States.

After completion of the transaction, HDI will continue operations in Florida, United States as a consolidated subsidiary of NIPRO. This transaction is a friendly acquisition that has been approved by the Boards of Directors of both NIPRO and HDI. The closing of the Tender Offer, however, is subject to the fulfillment of conditions based on the U.S. Antitrust Law and other general prerequisites.

1. Objectives of the HDI Acquisition

NIPRO Group has been striving to increase sales with its long-term business objective: net sales of 500,000 million yen in fiscal year 2020 and sales of 1,000,000 million yen in fiscal year 2030.

As we consider that growth of the Medical equipment division, our core business, will depend on the expansion of business in overseas markets, we have also been examining the improvement and enhancement of a business structure for marketing diabetes testing supplies globally, in addition to such products as insulin injection device and lancet device (skin puncture device) in the diabetes sphere, one of the fields we have focused on.

HDI is a leading manufacturer and marketer of diabetes testing supplies in the United States. HDI markets blood glucose meters such as TRUE2go™ and TRUEresult® through more than 45,000 pharmacies throughout the United States, including CVS, Rite Aid and Walgreens, as well as distributors such as AmerisourceBergen, Cardinal Health, McKesson, Invacare and Liberty Medical. HDI was named one of Forbes magazine's "200 Best Small Companies" in 2008, and in 2009 received high recognitions for the company's TRUE2go™, including a Medical Design Excellence Award (MDEA) and a Gold Award in the Medical/Test Equipment category, as part of the U.S. *appliance DESIGN* Magazine's 22nd Annual Excellence in Design (EID) Awards Competition.

NIPRO believes that the acquisition of HDI will provide the Group with a solid infrastructure for marketing our diabetes-related products in the USA and enable us to boost our presence in the global market by marketing HDI's products through NIPRO Group's sales network. Through these activities we will achieve the aforementioned long-term growth target for the Group and, as a global company, further enhance the satisfaction of medical personnel and patients around the world.

2. Outline of the Tender Offer

(1) The Tender Offeror

Nippon Product Acquisition Corporation

NIPRO has established an acquisition subsidiary, NPAC, in the USA. After completion of the Tender Offer, NPAC will be merged into HDI, which will subsequently become a consolidated subsidiary of NIPRO.

(2) Target of the Tender Offer

Home Diagnostics, Inc.

(3) Type of Shares to be Acquired in the Tender Offer

Common stock

(4) Tender Offer Price

US\$11.50 per share

We determined this offer price in negotiation with HDI after careful analysis and

consideration of assets, operations and forecasts of HDI, and after net asset value analysis, discounted cash flow analysis and comparable companies analysis.

(5) Funds required for the Tender Offer

Approximately US\$215 million (estimated amount)

The amount stated is the total consideration needed to purchase all outstanding shares of HDI and cash out certain stock options.

(6) Tender Offer Period

The Tender Offer is scheduled to commence within 10 business days following the date of the definitive agreement with HDI (February 2, 2010 U.S. time) and to remain open for 20 business days. Subject to the terms of the agreement, the Tender Offer period may be extended in the event that conditions of the Tender Offer are not fulfilled.

(7) Minimum Number of Shares to be Purchased

NPAC will purchase the tendered shares if more than 50% of HDI's outstanding shares (on a fully diluted basis) are tendered in the Tender offer.

(8) Changes in the percentage of HDI shares held as a result of the Tender Offer

Percentage of shares held prior to the Tender Offer 0%

Percentage of shares held after the Tender Offer 100% (in the event that all of HDI's shares are tendered in the Tender Offer)

3. Outline of HDI

- | | | |
|---|---|---------------------------|
| (1) Corporate Name | Home Diagnostics, Inc. | |
| (2) Business Description | Development, manufacturer and marketer of diabetes testing supplies for diabetes patients | |
| (3) Year of Incorporation | 1985 | |
| (4) Location of Head Office | Fort Lauderdale, Florida, USA | |
| (5) Name of Representative | Joseph H. Capper, President and Chief Executive Officer | |
| (6) Paid-in Capital | US\$169,000 (as of September 30, 2009) | |
| (7) Major Shareholders and Ownership (Based on Number of Shares Outstanding) (as of February 2, 2010) | | |
| | George H. Holley | 17.37% (3,040,732 shares) |
| | Judy Salem, individually and as executrix for The Estate of Robert Salem | 12.97% (2,201,386 shares) |
| | Royce & Associates LLC | 12.74% (2,150,784 shares) |
| | State of Wisconsin Investment Board | 7.56% (1,282,376 shares) |
| | Discovery Group I, LLC | 6.30% (1,072,241 shares) |

- Donald P. Parson 5.46% (949,159 shares)
- (8) Number of Shares Outstanding Common Stock 16,998,741 shares (as of January 27, 2010)
- (9) Relationship with NIPRO
NIPRO and HDI do not have any capital, personal or transactional relationships.
- (10) Fiscal Year End December
- (11) Number of Employees 571 (as of December 31, 2009)
- (12) Financial Results in Recent Fiscal Years

(Unit: US\$1,000)	December 2006	December 2007	December 2008
Consolidated Net Sales	112,628	115,601	123,582
Consolidated Operating Income	14,508	11,241	11,154
Consolidated Net Income	10,309	9,628	9,644
Consolidated Total Assets	117,676	130,251	140,580
Consolidated Net Assets	97,113	106,099	112,066

4. Prospects for the Future

NIPRO will disclose the impact of the Tender Offer and the Transaction, including the subsequent merger, on NIPRO Group's consolidated financial results and financial positions, as soon as the details become clear.

The tender offer described in this press release has not yet commenced. The purpose of this press release is to provide information only. This announcement is neither an offer to purchase, nor a solicitation of an offer to sell, shares of HDI's common stock. The tender offer will be conducted on the Tender Offer Statement on Schedule TO (containing an offer to purchase, forms of letters of transmittal and other documents relating to the tender offer) that NPAC files with the Securities and Exchange Commission ("SEC"). When these documents become available, investors and stockholders of HDI should read them carefully before making any decision respecting the tender offer, since these documents, which may be revised time to time, will contain important information regarding the tender offer. HDI investors and stockholders will be able to obtain a copy of these documents (when they become available) and other documents filed by NPAC with the SEC, at the website maintained by the SEC

<http://www.sec.gov>.